variable | category | PFS | OS | ||
---|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | ||
Smoking history | ever-smokers vs. never smoker | 1.9(1.31–2.76) | 0.001 | 2.206(1.43–3.40) | < 0.001 |
Smoking dosage | never smoker (PY = 0, Ref.) | 1 |  | 1 |  |
0 < PY ≤10 | 0.84(0.45–1.55) | 0.08 | 0.96(0.41–2.25) | 0.93 | |
11~ 30 PY | 2.95(1.76–4.94) | < 0.001 | 2.29(1.29–4.05) | 0.004 | |
>  30 PY | 8.33(4.18–16.75) | < 0.001 | 4.91(2.66–9.06) | < 0.001 | |
11~ 30 PY vs. > 30 PY | 2.97(1.35–6.56) | 0.007 | 2.22(1.08–4.57) | 0.03 | |
Age | > 60 vs. ≤ 60 years | 1.05(0.72–1.53) | 0.78 | 0.99(0.64–1.53) | 0.98 |
Sex | Male vs. female | 1.39(0.78–1.62) | 0.084 | 1.91(1.238–2.947) | 0.003 |
ECOG PS | ≥ 2 vs 0–1 | 1.76(0.99–3.12) | 0.05 | 3.12(1.73–5.62) | < 0.001 |
Stage | IV vs. recurrent or III | 1.23(1.03–1.46) | 0.02 | 1.4(1.1–1.9) | 0.02 |
Type of EGFR mutation | 19 del vs. 21 L858R | 1.2(0.81–1.7) | 0.36 | 0.66(0.38–1.15) | 0.15 |
Brain metastasis |  | 1.9(1.3–2.9) | 0.001 | 2.54(1.46–4.41) | 0.001 |
Line of targeted therapy | ≥2nd line vs. 1st | 1.15(0.80–1.64) | 0.439 | 1.92(1.25–2.93) | < 0.001 |
Histopathology | High vs. low to moderate grade adenocarcinoma | 1.17(0.81–1.69) | 0.39 | 0.91(0.51–1.65) | 0.78 |
Type of EGFR-TKI |  | 0.95(0.75–1.18) | 0.63 | 1.2 (0.53–2.69) | 0.66 |